Monash IVF (ASX: MVF) revenue holds near A$269m, but margin pressure cuts profit sharply

Monash IVF Group Limited (ASX: MVF) reported underlying net profit after tax of A$16.1 million for FY26, down 41.2% and below the A$17 million to A$18 million range provided in June. Revenue declined only 0.9% to A$269.5 million, but underlying EBITDA fell 19.5% to A$53.4 million and statutory net profit attributable to shareholders dropped 67.6% to A$8.3 million. The company declared a fully franked final dividend of 1.3 cents per share, taking FY26 dividends to 2.5 cents compared with 5.1 cents a year earlier.

The August 31 result arrived before the Australian market opened, so the A$0.68 August 28 close is the appropriate unaffected reference rather than any incomplete Monday trading move. MVF had already fallen from A$0.745 on August 21 to A$0.68 by August 28, a decline of approximately 8.7% over the five trading sessions preceding the results. Its 52-week range stood at approximately A$0.575 to A$0.895.

Why did Monash IVF profit fall 41% when group revenue declined by less than 1%?

The earnings deterioration came primarily from operating leverage working in reverse. Australian stimulated-cycle activity weakened while staffing, clinical and nursing costs did not decline proportionately with volumes, pushing those costs higher as a percentage of revenue. Monash IVF also incurred A$4.5 million of professional-services and additional-measures costs associated with incidents, compared with A$1.3 million in FY25, while commissioning, software-as-a-service and restructuring expenses added further pressure.

Underlying EBITDA margin fell to approximately 19.8% from about 24.4% in FY25. That roughly 4.6-percentage-point compression explains why a relatively modest revenue decline produced a much larger reduction in earnings. Underlying EBIT fell 34% to A$28.4 million, while higher depreciation, amortisation and borrowing costs increased the gap between EBITDA and the final profit available to shareholders.

The company had already warned in June that Australian assisted-reproductive-technology demand remained soft, with stimulated cycles across the broader market down 4.7% on a rolling three-month basis through April. At that point Monash IVF expected A$17 million to A$18 million of underlying NPAT, but the final A$16.1 million result came another 5% below the bottom of that revised range.

Is Monash IVF gaining or losing Australian IVF market share?

The answer depends on the measurement period. Monash IVF reported rolling 12-month domestic stimulated-cycle market share of 19.5% at June 30, down from 21% a year earlier. However, management said market share improved during the second half in several important states, particularly Victoria and New South Wales, and its June trading update had shown more recent rolling three-month national share around 20.1%.

That distinction matters because the FY26 earnings weakness reflects both market contraction and changes in Monash IVF’s own competitive position through the year. A company can lose share on a full-year comparison while simultaneously showing improving momentum exiting the period. FY27 therefore starts with better recent positioning than the 19.5% annual figure alone suggests, but the underlying Australian market still needs to stabilise for that improvement to translate efficiently into earnings growth.

International operations provided a useful counterweight. International revenue increased 15%, driven primarily by Malaysia, while genetics and ancillary revenue increased A$4.6 million through stronger preimplantation genetic testing activity and higher storage-fee income. Day-surgery activity also reached 7,980 procedures, while the company expects more surgical procedures to be performed in-house during FY27 following recent infrastructure investment.

Why did Monash IVF cash flow improve when profit declined so sharply?

Net operating cash flow increased to A$36.7 million from A$12.9 million, a 184% improvement, despite the weaker earnings result. Free cash flow moved to positive A$12.9 million from negative A$4.5 million, even after capital expenditure increased 65% to A$23.8 million.

The capital program included A$10.9 million for a Brisbane fertility clinic and day hospital, A$7.9 million for laboratory and medical equipment and A$5 million for information-technology hardware and systems. Those investments help explain why management expects a greater proportion of surgical activity to move into Monash IVF facilities during FY27, potentially allowing the group to capture more revenue per patient journey rather than outsourcing parts of the process.

Closing cash was A$8.84 million, slightly below A$9.43 million a year earlier, while the group had a net current-liability position of A$21.6 million. Management concluded that the business remained appropriately funded on a going-concern basis, but higher interest expense and continuing infrastructure requirements mean earnings recovery remains important to balance-sheet flexibility.

What has to improve for Monash IVF margins to recover in FY27?

Management expects cost-efficiency programs started during FY26 to contribute more strongly during FY27, while the largely completed infrastructure investment program should improve clinic utilisation and operating leverage. The immediate strategic focus is Victoria and New South Wales, where Monash IVF has been rebuilding specialist relationships and recent market-share trends have improved.

The company is also preparing for national assisted-reproductive-services regulatory reform and new ART-specific national safety and quality standards. That creates compliance costs but may favour larger providers with established clinical-governance systems, data infrastructure and specialist networks. Monash IVF has positioned its Nurture 2030 strategy around organic volume growth, doctor and patient engagement, and extracting better returns from its existing clinic footprint.

The dividend reduction demonstrates how much the earnings reset has already affected shareholders. FY26 dividends totalled 2.5 cents per share versus 5.1 cents in FY25, although the company’s stated policy remains a payout of approximately 60% to 70% of underlying NPAT. At the A$0.68 pre-results reference price, the 2.5-cent annual distribution equates to a trailing cash yield of roughly 3.7% before franking credits.

FY27 is therefore less about returning immediately to the earnings levels investors saw before the domestic IVF slowdown and more about showing that improved volumes flow through the existing cost base. Revenue was remarkably resilient in FY26 despite weaker domestic cycles; the problem was how little of that revenue reached the bottom line. A recovery in Australian demand combined with stronger international, genetics and in-house surgical contributions could therefore produce a disproportionately larger earnings response if cost growth is controlled.